drugset / Trial / NCT04303806

Effect of Rosuvastatin on the Clinical Features of Preeclampsia

NCT04303806

Phase 2 Unknown 80 enrolled Assiut University
RandomizedParallel-groupDouble-blindOther

Summary

The primary outcome will be the effect of rosuvastatin on the resolution of biochemical features associated with severe PE (↑CRP and IL6). .

Timeline

Start
2020-10
Primary completion
2022-10
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 20 mg Oral
Subject Rosuvastatin Small molecule 40 mg Oral

Indications